The ADC is also undergoing Phase III evaluation in patients at high risk of residual HL following autologous stem cell transplantation. A Phase II retreatment trial in relapsed patients who previously responded to brentuximab vedotin is in addition ongoing, along with a Phase I combination study evaluating brentuximab vedotin as front-line HL therapy. Seattle and Millennium are developing brentuximab vedotin under a collaboration agreement that gives Millennium's parent company Takeda rights to the drug worldwide, except for the U.S. and Canada, which are retained by Seattle. The firms are funding the development costs on a 50:50 basis worldwide except for Japan, where Takeda has sole responsibility for funding development. Earlier this month Seattle teamed up with Genmab for a research collaboration that aims to combine the ADC technology with Genmab's HuMax-TF antibody targeting the tissue factor antigen.